Praxis Precision Medicines (PRAX) has moved into focus after reporting Phase 2/3 POWER1 data for vormatrigine in focal onset seizures, missing the primary endpoint while hitting a key secondary measure and pausing the follow on POWER2 trial.

The vormatrigine setback has triggered a sharp pullback, with a 1 day share price return down 4.06% and a 7 day share price return down 27.42%. However, the 1 year total shareholder return is still very large and the 3 year total shareholder return is around 16x.

If recent volatility in Praxis has you reassessing the sector, this could be a moment to widen the search using Simply Wall St’s screener for central nervous system and epilepsy peers, or other high potential healthcare names alongside 39 healthcare AI stocks

With Praxis now valued at about US$7.4b and trading at a large discount to a US$627 price target alongside an indicated 91% intrinsic discount, the key question is whether recent weakness signals an opportunity or a market that already prices in future growth.

Most Popular Narrative: 43.4% Undervalued

Against the last close at $254, the most followed narrative points to a fair value of about $449, putting recent volatility into a very different context.

Multiple late stage epilepsy programs, including vormatrigine and relutrigine with breakthrough designation in severe genetic epilepsies, create a portfolio effect in a growing CNS innovation cycle. This increases the probability of multiple approvals and a step change in total company earnings over the back half of the decade.

Want to see what sits behind that earnings step change idea? The narrative focuses on rapid revenue expansion, margin repair and a premium profit multiple. The full breakdown shows how those pieces combine into the current fair value call.

Result: Fair Value of $449 (UNDERVALUED)

However, the story only holds if key epilepsy trials stay on track and vormatrigine convincingly translates into real world use, rather than stalling behind existing options.

Wall Street's queuing for one rocket. While SpaceX counts down to its IPO, other companies tied to the new space race are already in orbit. → 20 Compelling Space Companies watchlist · Global Space Race Investing Ideas screener · Scan the sector by valuation on Rocket Lab's valuation page.

Next Steps

After all this, are you feeling cautious or curious about where Praxis goes next? Act quickly, review both sides of the story, and weigh the 2 key rewards and 2 important warning signs.

Looking for more investment ideas?

If Praxis has sharpened your focus, do not stop here; use this momentum to compare other opportunities and pressure test your portfolio with fresh stock ideas.

• Spot potential bargains before the crowd by scanning companies that currently screen as 49 high quality undervalued stocks.
• Build a portfolio that aims for dependable income using the 9 dividend fortresses.
• Sleep easier by reviewing stocks that qualify for the 64 resilient stocks with low risk scores.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.